Decreased levels of serum platelet-activating factor acetylhydrolase in patients with rheumatic diseases

PAF is a potent inflammatory compound known to stimulate the release of various cytokines involved in rheumatic diseases. Elevated blood PAF levels are reported in these patients. We report that serum PAF acetylhydrolase activity (AHA) levels are decreased in patients with rheumatoid arthritis or os...

Descripción completa

Detalles Bibliográficos
Autores principales: Vergne, P., Praloran, V., Treves, R., Denizot, Y.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 1997
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2365831/
https://www.ncbi.nlm.nih.gov/pubmed/18472827
http://dx.doi.org/10.1080/09629359791758
_version_ 1782154227892617216
author Vergne, P.
Praloran, V.
Treves, R.
Denizot, Y.
author_facet Vergne, P.
Praloran, V.
Treves, R.
Denizot, Y.
author_sort Vergne, P.
collection PubMed
description PAF is a potent inflammatory compound known to stimulate the release of various cytokines involved in rheumatic diseases. Elevated blood PAF levels are reported in these patients. We report that serum PAF acetylhydrolase activity (AHA) levels are decreased in patients with rheumatoid arthritis or osteoarthritis as compared to healthy controls. Serum and synovial fluid AHA levels were correlated in these patients. The present study suggests the potential role of AHA in controling systemic and/or local PAF levels in patients with rheumatic diseases.
format Text
id pubmed-2365831
institution National Center for Biotechnology Information
language English
publishDate 1997
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-23658312008-05-12 Decreased levels of serum platelet-activating factor acetylhydrolase in patients with rheumatic diseases Vergne, P. Praloran, V. Treves, R. Denizot, Y. Mediators Inflamm Research Article PAF is a potent inflammatory compound known to stimulate the release of various cytokines involved in rheumatic diseases. Elevated blood PAF levels are reported in these patients. We report that serum PAF acetylhydrolase activity (AHA) levels are decreased in patients with rheumatoid arthritis or osteoarthritis as compared to healthy controls. Serum and synovial fluid AHA levels were correlated in these patients. The present study suggests the potential role of AHA in controling systemic and/or local PAF levels in patients with rheumatic diseases. Hindawi Publishing Corporation 1997-06 /pmc/articles/PMC2365831/ /pubmed/18472827 http://dx.doi.org/10.1080/09629359791758 Text en Copyright © 1997 Hindawi Publishing Corporation. http://creativecommons.org/licenses/by/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Vergne, P.
Praloran, V.
Treves, R.
Denizot, Y.
Decreased levels of serum platelet-activating factor acetylhydrolase in patients with rheumatic diseases
title Decreased levels of serum platelet-activating factor acetylhydrolase in patients with rheumatic diseases
title_full Decreased levels of serum platelet-activating factor acetylhydrolase in patients with rheumatic diseases
title_fullStr Decreased levels of serum platelet-activating factor acetylhydrolase in patients with rheumatic diseases
title_full_unstemmed Decreased levels of serum platelet-activating factor acetylhydrolase in patients with rheumatic diseases
title_short Decreased levels of serum platelet-activating factor acetylhydrolase in patients with rheumatic diseases
title_sort decreased levels of serum platelet-activating factor acetylhydrolase in patients with rheumatic diseases
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2365831/
https://www.ncbi.nlm.nih.gov/pubmed/18472827
http://dx.doi.org/10.1080/09629359791758
work_keys_str_mv AT vergnep decreasedlevelsofserumplateletactivatingfactoracetylhydrolaseinpatientswithrheumaticdiseases
AT praloranv decreasedlevelsofserumplateletactivatingfactoracetylhydrolaseinpatientswithrheumaticdiseases
AT trevesr decreasedlevelsofserumplateletactivatingfactoracetylhydrolaseinpatientswithrheumaticdiseases
AT denizoty decreasedlevelsofserumplateletactivatingfactoracetylhydrolaseinpatientswithrheumaticdiseases

Ejemplares similares